GeekWire

MARCH 8, 2022

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We million in 2020.

Biotechnology 105

Biotechnology .Net Programming Company 105

GeekWire

JUNE 30, 2021

The company, founded in 2011, began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other drug companies. Net losses were $14.4 2020 revenue was $4.7 million, up from $2 million for 2019. 2020 revenue was $4.7 million, up from $2 million for 2019.

Company 121

Company Biotechnology .Net Programming 121

CTOvision

FEBRUARY 10, 2016

The technology was developed under DARPA’s Reliable Neural-Interface Technology (RE-NET) program , and offers new potential for safely expanding the use of brain-machine interfaces (BMIs) to treat physical disabilities and neurological disorders.

.Net 150

.Net Biotechnology Research Study 150

GeekWire

DECEMBER 27, 2022

He’s now CEO of Nautilus Biotechnology, and he’s not taking any big chances in the current economic downturn. Earlier companies are considering fewer development programs and having a slower ramp on hiring. Neoleukin Therapeutics recently shed staff in the wake of disappointing clinical data for its lead program, for example.

Industry 99

Industry Biotechnology CTO Company 99

GeekWire

MARCH 17, 2023

That said, we do not anticipate any reductions in either company’s R&D programs due to the transaction,” said Bourla. Seagen reported $2 billion in revenue and a net loss of $610 million for 2022, along with $1.3 . “These targeted efficiencies would be across several functional lines by eliminating duplication.

Biotechnology 92

Biotechnology .Net Research Conference 92

GeekWire

JUNE 24, 2020

million net loss and $132.5 million net loss and $94.8 Accolade would be the first Seattle-area company to go public since Adaptive Biotechnologies last year. It plans to trade on the Nasdaq exchange under the ticker ACCD. The company’s latest S-1 registration filing shows a $51.3 That’s compared to a $56.5

.Net 86

.Net Biotechnology Healthcare Financial 86

Trends in the Living Networks

AUGUST 11, 2022

With a PhD in Planning and Innovation Studies, and a Master’s degree in Architecture, Urban Design and Urban Planning, Karuri-Sebina has a sound knowledge base for her work as Executive Manager of programs at the South African Cities Network. She has a solid understanding of technology and its ability to deliver business outcomes.

Study 148

Study Research Trends Education 148